HCV: Focus on Side Effects | Page 2

BY MICHAEL R. PAGE, PHARMD, RPH
PUBLISHED WEDNESDAY, JUNE 10, 2015
Medication Side effect Active Placebo Number of patients to treat to get 1 additional case
Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir) plus ribavirin Fatigue 32% 26% 16 to 17 patients
Nausea 22% 15% 14 to 15 patients
Pruritusa 18% 7% 9 to 10 patients
Skin reactions 16% 9% 14 to 15 patients
Insomnia 14% 7% 14 to 15 patients
Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir) Nausea 16% 8% 12 to 13 patients
Pruritusa 13% 7% 16 to 17 patients
Insomnia 12% 5% 14 to 15 patients
Astheniab 9% 4% 20 patients
Harvoni (ledipasvir and sofosbuvir) (side effects reported here are common side effects that occurred with 12 weeks of treatment) Fatigue 13% N/A Cannot be calculated as no placebo group data is reported in the package insert.
Headache 14% N/A
Nausea 7% N/A
Diarrhea 3% N/A
Insomnia 5% N/A
N/A = not applicable.

aPruritus is a condition of itchy skin.

bAsthenia is weakness, malaise, or lack of energy.

Recommended Articles
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
$auto_registration$